Relypsa, Inc. Initiates Open-Label Phase 2 Clinical Study of RLY5016 for the Management of Hyperkalemia

Published: Jun 16, 2010

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company’s lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.

Back to news